3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Cytarabine
146
Azacitidine
99
venetoclax
95
Cyclophosphamide
70
fludarabine
69
Decitabine
63
fludarabine phosphate
55
Specimen Handling
35
Filgrastim
35
Daunorubicin
34
Mitoxantrone
30
Idarubicin
29
Etoposide
27
Injections
25
Granulocyte Colony-Stimulating Factor
25
Biopsy
24
Busulfan
22
Tacrolimus
21
Clofarabine
21
Mycophenolic Acid
18
Melphalan
18
Methotrexate
17
Bortezomib
17
Whole-Body Irradiation
16
Stem Cell Transplantation
16
Peripheral Blood Stem Cell Transplantation
16
Vorinostat
15
Gemtuzumab
15
Lenalidomide
14
decitabine and cedazuridine drug combination
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myeloid, Acute
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled